PTUPB ameliorates high-fat diet-induced non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in mice.

In conclusion, dual inhibition of COX-2/sEH attenuates hepatic steatosis by inhibiting the NLRP3 inflammasome activation. PTUPB might be a promising potential therapy for liver steatosis associated with obesity.
PMID: 31973813 [PubMed - as supplied by publisher]

Source: Biochemical and Biophysical Research communications - January 19, 2020 Category: Biochemistry Authors: Sun CC, Zhang CY, Duan JX, Guan XX, Yang HH, Jiang HL, Hammock BD, Hwang SH, Zhou Y, Guan CX, Liu SK, Zhang J Tags: Biochem Biophys Res Commun Source Type: research